| Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone | Frank Vinluan | 09/06/19 | National |
| With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss | Ben Fidler | 09/03/19 | Boston |
| Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More | Frank Vinluan | 11/16/18 | National |
| Flagship Bags $618M, Its Largest Raise Ever, For a New Startup Crop | Corie Lok | 12/20/17 | Boston |
| Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More | Ben Fidler | 03/10/17 | National |
| Vertex Bags Concert’s Rival CF Drug For $160M, Plans Combo Studies | Ben Fidler | 03/06/17 | Boston |
| East Coast Biotech Roundup: Collins, Disruptors, Biogen, & More | Ben Fidler | 10/09/15 | Boston |
| East Coast Biotech Roundup: NY Bio, Synageva, Kadmon & More | Ben Fidler | 05/08/15 | New York |
| Investors Line up For Westphal as Muscle Cramp Startup Upsizes IPO | Ben Fidler | 01/28/15 | Boston |
| Big Events, Exits Raising Boston’s Innovation Profile at Year’s End | Gregory T. Huang | 12/12/14 | Boston |
| East Coast Biotech Roundup: Biogen, Civitas, Rhythm, Alkermes, & More | Alex Lash | 08/29/14 | Boston |
| Xconomy Boston’s Top Stories of Q2 2014: Editor’s Picks | Gregory T. Huang | 07/01/14 | Boston |
| East Coast Biotech Roundup: Concert, Merrimack, Vertex, & More | Ben Fidler | 05/02/14 | Boston |
| How A Kidney Drug Almost Torpedoed Concert Pharma’s IPO | Ben Fidler | 04/25/14 | Boston |
| East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More | Ben Fidler | 02/14/14 | Boston |
| Concert Pharma Heads to Nasdaq, Prices IPO at $14 Per Share | Ben Fidler | 02/13/14 | Boston |
| East Coast Biotech Roundup: JP Morgan Edition | Ben Fidler | 01/17/14 | Boston |
| Celgene Emerges as Biotech’s Shrewdest, Nimblest Dealmaker | Luke Timmerman | 08/05/13 | National |
| Trusting Your Partners: A Chat With Celgene’s George Golumbeski | Ben Fidler | 07/11/13 | New York |
| East Coast Life Sciences Roundup: Dunsire, Good Start, Nimbus, & More | Ben Fidler | 05/10/13 | Boston |
| Concert Pharma To Get $300M+ Per Drug in Celgene Pact | Ben Fidler | 05/06/13 | Boston |
| East Coast Life Sciences Roundup: Third Rock, SciFluor, Cubist | Bernadette Tansey | 03/01/13 | Boston |
| Concert Pharma, Jazz Pharma Strike $120M Deal for Narcolepsy | Luke Timmerman | 02/26/13 | Boston |
| BG Medicine, Bottomline, 4s3 Bioscience Among the Week’s Dealmakers | Erin Kutz | 03/07/12 | Boston |
| Concert, Alere, TremRx, & More Names from Boston Life Sciences News | Erin Kutz | 03/02/12 | Boston |
| SD Life Sciences (and Cleantech) Roundup: DexCom, Ligand, Genomatica | Bruce V. Bigelow | 03/01/12 | San Diego |
| Concert Nabs $200M Deal From Avanir to Make Psych Drugs | Luke Timmerman | 02/29/12 | Boston |
| Verastem, the 15-Month Old Christoph Westphal Venture in Cancer Stem Cells, Seeks IPO | Luke Timmerman | 11/03/11 | Boston |
| Biogen Eyes Cambridge Move, Vertex Licenses Alios Drugs, Concert Nabs GSK Payment, & More Boston-Area Life Sciences News | Erin Kutz | 06/24/11 | Boston |
| Concert Pharmaceuticals Hits $4 Million Milestone in GSK Alliance | Arlene Weintraub | 06/20/11 | Boston |
